

中国药学会系列期刊/《CAJ-CD》规范执行优秀期刊/美国《化学文摘》荷兰SCOPUS等国际著名检索系统收录
中国中文核心期刊 中国科技核心期刊 中国科学引文数据库来源期刊




Q K 1 8 0 9 5 7 8

CHINESE JOURNAL OF NEW DRUGS

中國新药杂志

ISSN 1003-3734
CN 11-2850/R
CODEN ZXZHA6



2
2018
Vol.27 | No.2

我国中药专利涉及创造性法条的司法判例分析
2005—2016年我国I类新药申报审批情况分析
抗病毒药物制剂新技术与作用新靶点研究进展
苯丙酮尿症及相关治疗方法研究进展
UPLC-MS/MS研究抗肿瘤化合物HK-7在不同种属肝微粒体中的
代谢稳定性和代谢酶表型

www.newdrug.cn

ISSN 1003-3734



02>

9 771003 373187
万方数据

国家食品药品监督管理总局主管



- 新药述评与论坛•
- 129 我国中药专利涉及创造性法条的司法判例分析.....张朝磊, 赵良, 卞志家, 等
- 134 浅谈《化学药品注册分类改革工作方案》实施后对化学药品研发的影响及对策.....唐金睿, 孙敏, 徐丽丽
- 138 内标在LC-MS法生物样品分析中的相关问题探讨.....杜晓琳, 黄娟, 刘小娟, 等
- 新药注册与审评技术•
- 142 2005—2016年我国I类新药申报审批情况分析.....樊玉录, 陈玉文
- 重大新药创制专项巡礼•
- 147 抗病毒药物制剂新技术与作用新靶点研究进展.....侯冠华, 邱瑞桂, 高春生
- 综述•
- 154 苯丙酮尿症及相关治疗方法研究进展.....牛瑞青, 冯文化
- 159 哮喘和慢性阻塞性肺疾病用药现状及新药研究进展.....喻勇, 宁保明, 舒宏, 等
- 临床研究•
- 167 正葡萄糖钳夹中建立高胰岛素平台与否对内源性胰岛素分泌的影响.....刘辉, 喻红玲, 柳佳利, 等
- 173 重组人促红细胞生成素治疗胃肠道恶性肿瘤化疗相关性贫血的临床观察.....赵成民, 黄带发, 张丽辉, 等
- 实验研究•
- 178 UPLC-MS/MS研究抗肿瘤化合物HK-7在不同种属肝微粒体中的代谢稳定性和代谢酶表型.....夏媛媛, 杨沮勤, 朱伊婷, 等
- 184 缬沙坦对糖尿病肾病大鼠足细胞自噬的影响.....王晓丹, 高丽辉, 牛艳芬, 等
- 190 黄芩苷对尿酸钠诱导RAW264.7细胞NLRP3及炎症因子表达的影响.....文学平, 刘德俊, 裴忆雪, 等
- 195 肾康注射液对腹膜纤维化小鼠E-cadherin和 α -SMA动态表达的影响.....王玉得, 安雅臣, 蒋艳茹, 等
- 203 沙格列汀合成路线的改进.....曹文婷, 贺欢, 张俏艳, 等
- 207 双靶向多功能纳米载体的构建与评价.....宋晓燕, 王晓英, 亓梦娇, 等
- 214 洋托拉唑钠缓释生物黏附片的处方筛选及体外释放度考察.....孙陶利, 江妹, 蒋瑶, 等
- 220 马来酸阿塞那平微球的制备及体外释放研究.....周祥萍, 何冬梅, 杨娟, 等
- 225 黄葵素平衡溶解度和表观油水分配系数的测定.....刘蔓, 李辉, 丁劲松
- 药物安全与合理应用•
- 229 PD-1单抗/PD-L1单抗与多西他赛治疗进展期非小细胞肺癌疗效与安全性的荟萃分析.....万秋, 杨扬, 黎友伦
- 236 达沙替尼上市后呼吸系统不良反应信号的检测与分析.....田雅兰, 边桂芝, 曹培, 等
- 242 心脏起搏器置入术后环磷腺苷致神经系统不良反应1例.....黄红娜, 田丹丽, 张建红, 等
- 245 临床药师在老年痴呆科多学科团队诊疗工作中的实践与体会.....孙艳萍, 蔡郁, 吕继辉, 等

- 129 Analysis of judicial precedent of traditional Chinese medicine patent-related creative law ZHANG Chao-lei, ZHAO Liang, BIAN Zhi-jia, *et al*
- 134 A brief analysis of the influence of implementation of work program for the Reform of Classification of Chemical Medicine Registration on the research and development of chemical medicines in China and the countermeasures TANG Jin-rui, SUN Min, XU Li-li
- 138 Discussion about internal standards in LC-MS for bioanalysis DU Xiao-lin, HUANG Juan, LIU Xiao-juan, *et al*
- 142 An analysis of the registration and approvals for class I of innovative drug during 2005—2016 in China FAN Yu-lu, CHEN Yu-wen
- 147 Advances in formulation approach and action targets of novel antiviral drugs HOU Guan-hua, QIU Rui-gui, GAO Chun-sheng
- 154 Research progress of phenylketonuria and its relevant treatment NIU Rui-qing, FENG Wen-hua
- 159 Current status and new development of drugs for asthma and chronic obstructive pulmonary disease YU Yong, NING Bao-ming, SHU Hong, *et al*
- 167 Inhibiting effect of establishment of peripheral hyperinsulinemia on endogenous insulin secretion when using euglycemic clamp technique LIU Hui, YU Hong-ling, LIU Jia-li, *et al*
- 173 Clinical observation of recombinant human erythropoietin on chemotherapy-induced anemia in patients with gastrointestinal cancer ZHAO Cheng-min, HUANG Dai-fa, ZHANG Li-hui, *et al*
- 178 Investigation of metabolic stability and metabolic enzyme phenotypes of anti-tumor compound HK-7 in different species of liver microsomes by UPLC-MS/MS XIA Yuan-yuan, YANG Ju-qin, ZHU Yi-ting, *et al*
- 184 Effects of valsartan on podocyte autophagy in rats with diabetic nephropathy WANG Xiao-dan, GAO Li-hui, NIU Yan-fen, *et al*
- 190 Effect of baicalin on the expression of NLRP3 inflammasome and inflammatory factors in monosodium urate-induced RAW264.7 macrophages WEN Xue-ping, LIU De-jun, PEI Yi-xue, *et al*
- 195 Experimental study of the effects of SKI on peritoneal fibrosis relating to peritoneal dialysis WANG Yu-xun, AN Ya-chen, JIANG Yan-ru, *et al*
- 203 Improvement of synthetic route of saxagliptin CAO Wen-ting, HE Huan, ZHANG Qiao-yan, *et al*
- 207 Design and evaluation of dual targeting multifunctional nanocarrier SONG Xiao-yan, WANG Xiao-ying, QI Meng-jiao, *et al*
- 214 Preparation of pantoprazole sodium bioadhesive tablets SUN Tao-li, JIANG Mei, JIANG Yao, *et al*
- 220 Preparation and *in vitro* release of asenapine maleate-loaded microspheres ZHOU Xiang-ping, HE Dong-meい, YANG Juan, *et al*
- 225 Determination of equilibrium solubility and apparent oil/water partition coefficient of berberine α -hydroxy β -decanoylethyl sulfonate LIU Man, LI Hui, DING Jin-song
- 229 Efficacy and safety of PD-1 antibody/PD-L1 antibody versus docetaxel in non-small-cell lung cancer: a Meta-analysis WAN Qiu, YANG Yang, LI You-lun
- 236 Detection and evaluation of dasatinib-induced respiratory system ADR signals in post-marketing experience TIAN Ya-lan, BIAN Gui-zhi, CAO Pei, *et al*
- 242 Adverse reaction of adenosine cyclophosphate in nervous system after pacemaker implantation HUANG Hong-na, TIAN Dan-li, ZHANG Jian-hong, *et al*
- 245 Practice and experience of clinical pharmacists in the multidisciplinary team of senile dementia department SUN Yan-ping, CAI Yu, LÜ Ji-hui, *et al*

Directed by: China Food and Drug Administration

Sponsored by: China Medical Science Press
China National Pharmaceutical Group Corp.
Chinese Pharmaceutical Association

Editor-in-Chief: SANG Guo-wei

Board Chairman: SHI Sheng-ji

Edited by: Editorial Board of Chinese Journal of New Drugs

Published by: Chinese Journal of New Drugs Co., Ltd.

Address: Room 317, No.3 Chengming Building, No.2 Xizhimen South Street, Xicheng District, Beijing 100035, China

Tel: (010)52722697 / 52722651 / 52723707

Website: <http://www.newdrug.cn>

E-mail: bianjibu@newdrug.cn

Printer: Beijing Kexin Printing Co., Ltd.

Domestic Distribution: Beijing Post Offices

Overseas Distribution: China International Book Trading Corp.
(P.O.Box 399 Beijing, China)

Domestic Subscription: Local Post Offices

Periodical Registration: ISSN 1003-3734 CN 11-2850/R

Publication Date: January 30, 2018

Copyright: 2018 by Chinese Journal of New Drugs Co.,Ltd.



睛众®
富马酸替诺福韦二吡呋酯片
Tenofovir Disoproxil Fumarate Tablets

广告

臻睛真意惠万家

慢性乙型肝炎抗病毒治疗一线药物
国内率先通过《仿制药质量和疗效一致性评价》
开展与原研替诺福韦酯五年期“头对头”临床试验



睛众®简要处方资料

【药品名称】商品名：睛众®

通用名：富马酸替诺福韦二吡呋酯片

【适 应 症】本品适用于治疗慢性乙型肝炎成人和≥12岁的儿童患者；
与其他抗逆转录病毒药物联用，治疗成人HIV-1感染。

【规 格】300mg

【用法用量】成人和12岁及以上儿童患者（35kg或以上）口服本品，每日1次，每次300mg，
可空腹或与食物同服。

【不良反应】临床试验中最常见的不良反应包括消化道事件、头痛、头晕、乏力、鼻咽炎、
疼痛、皮疹、抑郁、失眠、淀粉酶增加、肝酶升高和肌酐升高等。

【禁 忌】富马酸替诺福韦二吡呋酯禁用于先前对本药物中任何一种成份过敏的患者。



(详细资料备索)

苏药广审（文）：第2017120671号

@ HTTP://WWW.CTTQ.COM

健康咨询热线: 800 828 5598

本广告仅供医学、药学专业人士阅读

万方数据

国内定价: 30.00元 国内统一刊号CN11-2850/R 邮发代号82-488 国外代号M4240

正大天晴药业集团

CHIA TAI TIANQING PHARMACEUTICAL GROUP